Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

This study has been completed.
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG Identifier:
First received: March 30, 2006
Last updated: March 8, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2009
  Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)